Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for China Pharma Holdings (CPHI) over the last 14 years, with Q3 2025 value amounting to $25302.0.

  • China Pharma Holdings' Asset Writedowns and Impairment rose 162789.86% to $25302.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $227467.0, marking a year-over-year increase of 6072.91%. This contributed to the annual value of $450738.0 for FY2024, which is 296055.72% up from last year.
  • China Pharma Holdings' Asset Writedowns and Impairment amounted to $25302.0 in Q3 2025, which was up 162789.86% from $2032.0 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Asset Writedowns and Impairment ranged from a high of $213379.0 in Q1 2025 and a low of -$403601.0 during Q4 2021
  • Over the past 5 years, China Pharma Holdings' median Asset Writedowns and Impairment value was -$1656.0 (recorded in 2024), while the average stood at -$4994.3.
  • Per our database at Business Quant, China Pharma Holdings' Asset Writedowns and Impairment tumbled by 98193.98% in 2022 and then soared by 162789.86% in 2025.
  • China Pharma Holdings' Asset Writedowns and Impairment (Quarter) stood at -$403601.0 in 2021, then surged by 97.49% to -$10136.0 in 2022, then soared by 183.31% to $8444.0 in 2023, then plummeted by 256.87% to -$13246.0 in 2024, then soared by 291.02% to $25302.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $25302.0 for Q3 2025, versus $2032.0 for Q2 2025 and $213379.0 for Q1 2025.